Investigational drug · Phase 3
Bupropion Sustained-Release
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Major Depressive Disorder (MDD).
Phase 3Last checked: Nov 20, 2026Latest source record: May 6, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
42
Any phase or sponsor naming "Bupropion Sustained-Release"
First trial start
2025
Apr 11, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Bupropion Sustained-Release", any sponsor or status.
Conditions studied
As listed on its trial records.
- Major Depressive Disorder (MDD)
Approved drugs for the same conditions: Depression (major depressive disorder) · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "Bupropion Sustained-Release" as an intervention, largest first.
- A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese SubjectsPivotal-lookingCompleted
Orexigen Therapeutics, IncIndustry
NCT00532779 · 1,742 participants · Start Oct 2007 · Primary completion May 2009
Drug: Naltrexone SR 16 mg/Bupropion SR 360 mg /day; Naltrexone SR 32 mg/Bupropion SR 360 mg /day and 1 more · For: Obesity; Overweight
Sites: Birmingham, Alabama; Fairhope, Alabama; Chandler, Arizona · 34 sites in all
- A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese SubjectsPivotal-lookingCompleted
Orexigen Therapeutics, IncIndustry
NCT00567255 · 1,496 participants · Start Dec 2007 · Primary completion Jun 2009
Drug: Naltrexone SR 32 mg/bupropion SR 360 mg/day; Placebo · For: Obesity; Overweight
Sites: Phoenix, Arizona; Hot Springs, Arkansas; Carmichael, California · 36 sites in all
- A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification ProgramPivotal-lookingCompleted
Orexigen Therapeutics, IncIndustry
NCT00456521 · 793 participants · Start Mar 2007 · Primary completion Dec 2008
Drug: Naltrexone SR 32 mg/ bupropion SR 360 mg/ day; Placebo · For: Obesity; Overweight
Sites: La Jolla, California; Denver, Colorado; Gainesville, Florida · 9 sites in all
- Randomized Trial of Ultrashort Psychotherapy vs Sustained-Release Bupropion for Smoking CessationPivotal-lookingCompleted
Medical University InnsbruckAcademic, hospital or other
NCT00484692 · 779 participants · Start Jul 2005
Drug: sustained-release bupropion (Zyban(R)) · For: Nicotine Dependence; Substance Abuse; Substance Dependence and 1 more
Sites: Graz, Austria
- Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With ObesityPivotal-lookingCompleted
Orexigen Therapeutics, IncIndustry
NCT00709371 · 729 participants · Start Jul 2008 · Primary completion Apr 2009
Drug: Zonisamide SR placebo/ bupropion SR placebo; Zonisamide SR placebo/ bupropion SR 360 mg/day and 4 more · For: Obesity
Sites: Fairhope, Alabama; La Jolla, California; Denver, Colorado · 20 sites in all
- Nicotine Patch and Bupropion to Reduce Smoking Rates in Younger, Low-Income, and Minority IndividualsPivotal-lookingCompleted
University of TennesseeAcademic, hospital or other
NCT00308763 · 594 participants · Start Jan 2004 · Primary completion Dec 2008
Drug: Nicotine Patch; Sustained Release Bupropion · For: Tobacco Use Disorder
Sites: Memphis, Tennessee
- Maintenance Treatment for Abstinent SmokersPivotal-lookingCompleted
National Institute on Drug Abuse (NIDA)NIH
NCT00063323 · 589 participants · Start Aug 2000 · Primary completion Jul 2006
Drug: Bupropion · For: Tobacco Use Disorder
Sites: New York, New York
- A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01138007 · 572 participants · Start Jun 17, 2010 · Primary completion Aug 1, 2012
Drug: 323U66 SR 150 mg tablet; 323U66 SR 150 mg placebo tablet · For: Depressive Disorder, Major
Sites: Aichi, Japan; Fukuoka, Japan; Fukushima, Japan · 59 sites in all
- A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 DiabetesPivotal-lookingCompleted
Orexigen Therapeutics, IncIndustry
NCT00474630 · 505 participants · Start May 2007 · Primary completion Jun 2009
Drug: Naltrexone SR 32 mg/bupropion SR 360 mg/ day; Placebo · For: Obesity; Overweight; Diabetes Mellitus, Type 2
Sites: Fairhope, Alabama; Peoria, Arizona; Phoenix, Arizona · 53 sites in all
- Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive DisorderPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00351910 · 494 participants · Start May 2006
Drug: Quetiapine; Amitriptyline and 8 more · For: Major Depressive Disorder
Sites: Everton Park, Australia; Southport, Australia; Frankston, Australia · 72 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Design and Baseline Characteristics of CONCORD, a Trial of Novel Therapies for Depression in CKD.
McAdams MC, Gregg LP, Carmody T, et al. · Kidney Int Rep 2026
- Tobacco Use Treatment: Synopsis of the 2026 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline.
Myers MG, Vu PA, Calhoun PS, et al. · Ann Intern Med 2026
- Randomized controlled trial of a group-based smoking cessation intervention for adults with serious mental illness.
Whitmore H, Hubbard E, Cooper B, et al. · Nicotine Tob Res 2026
- What are the clinical implications of mixed features in major depressive disorder? A VAST-D report.
Zisook S, Davis LL, Suppes T, et al. · J Psychopharmacol 2026
- When to use first-generation anti-obesity medications: Mechanisms, clinical indications, and patient-focused selection.
Burguera B, Griebeler ML, Al-Husni D · Adv Pharmacol 2026
- Tirzepatide Affect Sexual Function in Women: Case Report.
Mohammed GF, Al-Dhubaibi MS, Bahaj SS, et al. · Clin Med Insights Case Rep 2025
Also in development for Major Depressive Disorder (MDD)
- KH607Phase 34 trials
Chengdu Kanghong Pharmaceutical Group Co., Ltd. · Major Depressive Disorder (MDD), Postpartum Depressive Disorder
- CYB003Phase 33 trials
Cybin IRL Limited · Major Depressive Disorder, Major Depressive Disorder (MDD), Depression in Adults
- DT-101Phase 22 trials
Draig Therapeutics Ltd · Major Depressive Disorder (MDD)
- SPT-300LYT-300, GlyphAlloPhase 22 trials
Seaport Therapeutics · Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
- ACP-211Phase 21 trial
ACADIA Pharmaceuticals Inc. · Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
- NH102Phase 21 trial
Jiangsu Nhwa Pharmaceutical Co., Ltd. · Major Depressive Disorder (MDD)
- SPN-821Phase 21 trial
Supernus Pharmaceuticals, Inc. · Major Depressive Disorder (MDD)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.